Join your scheduled visit and view details of your treatment request.

Orders

My Appointments

Edit personal details, add contact info, and update preferences.

Profile

Update your card information and add new cards.

Payment Methods

Security

Talk with our patient support team to get help.

Support

Thank you for telling us a bit about yourself. Based on information provided, this treatment may not be appropriate at this time.
&nbsp;
Please contact your local healthcare provider to discuss your options.

upscriptlogo-2

upscriptLogo

You didn't finish, continue to see if Sofdra is right for you!

stethoscope2x-8

Stethoscope@2X

Provider review co-pay

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION Sofdra™ (sofpironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older. IMPORTANT SAFETY INFORMATION Sofdra is for use on the skin in the underarm area only. After applying Sofdra, wash your hands right away and do not touch your underarms. Sofdra is flammable. Avoid heat and flame while applying Sofdra. Who should not use Sofdra? Do not use Sofdra if you have certain medical conditions that can be made worse by taking an anticholinergic medicine, such as glaucoma, severe ulcerative colitis (UC) or other serious bowel problems, myasthenia gravis, and Sjogren’s syndrome. What should I tell my healthcare provider before using Sofdra? <ul> <li>Tell your healthcare provider about all of your medical conditions, including prostate, bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if Sofdra will harm your unborn baby or pass into your breast milk.</li> <li>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, especially any anticholinergic medicines.</li> </ul> What are possible side effects of Sofdra? Serious side effects may include: <ul> <li>Urinary retention. Stop using Sofdra and call your healthcare provider right away if you have difficulty urinating, urinate frequently or in a weak stream or drips, a full bladder or difficulty emptying your bladder.</li> <li>Problems with control of your body temperature. Stop using Sofdra and call your healthcare provider right away if you have decreased sweating that develops into symptoms of heat illness (e.g., hot, red skin; passing out; fast, weak pulse; fast, shallow breathing; increased body temperature).</li> <li>Blurred vision. Stop using Sofdra, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear. </li> </ul> The most common side effects of Sofdra include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes; and problems with urination. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program" target="_blank">www.fda.gov/medwatch</a> or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337. Keep Sofdra and all medicines out of the reach of children. Please see full <a href="https://www.sofdra.com/pdfs/prescribing-information.pdf" target="_blank">Prescribing Information</a>, <a href="https://www.sofdra.com/pdfs/patient-information.pdf" target="_blank">Patient Product Information</a>, and <a href="https://www.sofdra.com/pdfs/instructions-for-use.pdf" target="_blank">Instructions for Use</a>.

Live Chat

Phone

Video Chat

sofdra_woman_2250x1500

Sofdra_Woman_2250x1500

Simply answer a few medical questions without obligation to learn if Sofdra may be right for you. Are you here for yourself or your child that is 9 years of age or older?

Get Sofdra™ now!

<a href="https://sendrx.com/sofdra" target="_blank"> I already have a Sofdra prescription </a>

sofdra

2nd product

Telehealth

Get Started

Learn More

Treatments

Legal Documents

Speaking with our expert telehealth team is fast and easy. Email, call us, or start a live chat below.

Need Help?

Drospirenone and Estetrol tablets 3 mg/14.2 mg

box-wlines

Box-wLines

NEXTSTELLIS

GlobalSettings - GetSofdra WP Admin

Home

GlobalSettings

Upscript Health QA

GetSofdra

My Account

FAQs

How It Works

IMPORTANT SAFETY INFORMATION AND INDICATION

Welcome to GetSofdra.com, the exclusive telehealth site for Sofdra. Begin by registering and answering a few medical questions to see if Sofdra may be right for you. Then connect with a telehealth provider.** If prescribed Sofdra, get fast, free delivery to your door.

Get Sofdra™ for $0 pharmacy copay* Sweat less, pay less

Answer a few questions about yourself and your symptoms.

https://ush-dev-s3-sfwp-images-public.s3.us-west-2.amazonaws.com/wp-content/uploads/2024/02/20080434/Med-Folder%402x.png

1. Register and complete medical questionnaire

Connect with an independent telehealth provider at your convenience at the place of your choice.

https://ush-dev-s3-sfwp-images-public.s3.us-west-2.amazonaws.com/wp-content/uploads/2024/02/20080418/Calendar%402x.png

2. Schedule and pay for your telehealth visit

If Sofdra is right for you, request a prescription during your visit.

https://ush-dev-s3-sfwp-images-public.s3.us-west-2.amazonaws.com/wp-content/uploads/2024/02/20080438/Mobile-Holding%402x.png

3. Speak with a telehealth provider

Once your prescription is approved, Sofdra will be delivered directly to you.

https://ush-dev-s3-sfwp-images-public.s3.us-west-2.amazonaws.com/wp-content/uploads/2024/02/20080431/Mail-Box%402x.png

4. Receive your prescription

You can connect with an independent licensed healthcare provider from the comfort of your home.

Connect with a telehealth provider

We carry top brands and generics alike for exactly what your body needs.

https://ush-qa-s3-sfwp-images-public.s3.us-west-2.amazonaws.com/wp-content/uploads/20210314063722/birth_control_for_whom_1.png

Familiar relief

Choose your treatment, verify it’s right for you, and receive via mail or pickup.

https://ush-qa-s3-sfwp-images-public.s3.us-west-2.amazonaws.com/wp-content/uploads/20210129102333/processOverview_2.png

Direct orders

Our secure platform gives you confidence to try treatments and find what works.

https://ush-qa-s3-sfwp-images-public.s3.us-west-2.amazonaws.com/wp-content/uploads/20210129102334/processOverview_3.png

Respect for privacy

test tg title

*With commercial insurance, such as employer-sponsored plans. Offer not available to patients with federal or state government-funded insurance, such as Medicare, Medicaid, Tricare, and CHIP. Offer <a href="https://www.sofdra.com/pdfs/terms-and-conditions.pdf" target="_blank" style="text-decoration: underline;">terms and conditions</a> apply. **Single $35 telehealth visit fee To learn more about Sofdra, <a href="https://sofdra.com" target="_blank" style="font-weight: bold; text-decoration: underline;">click here</a>. <a href="https://sendrx.com/sofdra" target="_blank" style="font-weight: bold; text-decoration: underline;"> I already have a Sofdra prescription </a>

Learn how Sofdra can help treat your excessive sweating and request a prescription. If approved, we'll ship your prescription directly to your doore

UpScript gives you fast access to trusted prescription medication. Select your treatment, speak with a private online doctor and get it delivered right to your doorstep.

home page social

Get Sofdra | Hyperhidrosis | Excessive Sweating Treatment

Home page

home page

Register, access your account details, schedule and pay for your online visit all in one place. For parents registering their child for a prescription, begin by entering your child's first and last name below. Ensure all information provided on the following pages is accurate and specific to your child. Already registered? Please click the "Already have an account?" link on this page to log in.

Welcome to GetSofdra

No problem, let us know the email on your account and we’ll send you a link to reset.

Need to reset your password?

If you have an account, you should receive an email shortly with a link to reset your password. When you find it, click the link inside to reset your password.

If you do not receive the email within a few minutes, please contact patient support.

Check Your Email

Welcome back! 

Talk to an independent, licensed telehealth provider today to see if Sofdra might be right for you. Log in to get started.

Login | GetSofdra | Excessive Sweat Treatment

login

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
&nbsp;
See full prescribing information for complete boxed warning. 
Females over 35 years old who smoke should not use NEXTSTELLIS
&nbsp;
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.
<hr />
IMPORTANT SAFETY INFORMATION FOR NEXTSTELLIS® (drospirenone and estetrol tablets 3 mg/14.2 mg)
&nbsp;
HIGHLIGHTS OF PRESCRIBING INFORMATION
&nbsp;
These highlights do not include all the information needed to use NEXTSTELLIS safely and effectively. See full prescribing information for NEXTSTELLIS.
&nbsp;
NEXTSTELLIS (drospirenone and estetrol tablets), for oral use 
Initial U.S. Approval: 2021
&nbsp;
INDICATIONS AND USAGE
&nbsp;
NEXTSTELLIS is a combination of drospirenone, a progestin, and estetrol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy.
&nbsp;
Limitations of Use
&nbsp;
NEXTSTELLIS may be less effective in females with a BMI ≥30 kg/m2. In females with BMI ≥30 kg/m2, decreasing effectiveness may be associated with increasing BMI.
&nbsp;
DOSAGE AND ADMINISTRATION
<ul>
<li>Take one tablet by mouth at the same time every day.</li>
<li>Take tablets in the order directed on the blister pack.</li>
</ul>
DOSAGE FORMS AND STRENGTHS
NEXTSTELLIS consists of 28 tablets in the following order:
<ul>
<li>24 pink active tablets each containing drospirenone 3 mg and estetrol 14.2 mg</li>
<li>4 white inert tablets</li>
</ul>
CONTRAINDICATIONS
<ul>
<li>A high risk of arterial or venous thrombotic diseases</li>
<li>Current or history of a hormonally-sensitive malignancy (e.g., breast cancer)</li>
<li>Hepatic adenoma, hepatocellular carcinoma, acute hepatitis or decompensated cirrhosis</li>
<li>Co-administration with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir</li>
<li>Abnormal uterine bleeding that has an undiagnosed etiology</li>
<li>Renal impairment</li>
<li>Adrenal insufficiency</li>
</ul>
WARNINGS AND PRECAUTIONS
<ul>
<li>Thromboembolic Disorders and Other Vascular Problems: Stop NEXTSTELLIS if a thrombotic or thromboembolic event occurs. Start no earlier than 4 weeks after delivery. Consider all cardiovascular risk factors before initiating in any female, particularly in the presence of multiple risk factors.</li>
<li>Hyperkalemia: Check serum potassium concentration during the first NEXTSTELLIS treatment cycle in females on long-term treatment with medications that may increase serum potassium concentration.</li>
<li>Hypertension: Monitor blood pressure periodically and stop use if blood pressure rises significantly.</li>
<li>Migraine: Discontinue if new, recurrent, persistent, or severe migraines occur.</li>
<li>Hormonally-Sensitive Malignancy: Discontinue NEXTSTELLIS if a hormonally-sensitive malignancy is diagnosed.</li>
<li>Liver Disease: Withhold or permanently discontinue for persistent or significant elevation of liver enzymes.</li>
<li>Glucose Tolerance and Hypertriglyceridemia: Monitor glucose in females with prediabetes or diabetes. Consider an alternate contraceptive method for females with hypertriglyceridemia.</li>
<li>Gallbladder Disease and Cholestasis: Consider discontinuing NEXTSTELLIS in females with symptomatic gallbladder or cholestatic disease.</li>
<li>Bleeding Irregularities and Amenorrhea: May cause irregular bleeding or amenorrhea. Evaluate for other causes if symptoms persist.</li>
</ul>
ADVERSE REACTIONS
Most common adverse reactions (≥2%): bleeding irregularities, mood disturbance, headache, breast symptoms, dysmenorrhea, acne, weight increased, and libido decreased
DRUG INTERACTIONS
<ul>
<li>CYP3A Inducers: May lead to contraceptive failure and/or increase breakthrough bleeding. Avoid concomitant use. If concomitant use is unavoidable, use an alternative or back-up contraceptive method during co-administration and up to 28 days after discontinuation of the CYP3A inducer.</li>
<li>See full Prescribing Information for additional clinically significant drug interactions.</li>
</ul>
USE IN SPECIFIC POPULATIONS
<ul>
<li>Pregnancy: Discontinue if pregnancy occurs.</li>
<li>Lactation: Advise postpartum females that NEXTSTELLIS can decrease milk production.</li>
</ul>
To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf" target="_blank" rel="noopener">PATIENT COUNSELING INFORMATION and FDA-approved patient labeling</a>.
BMI=body mass index; COC=combined oral contraceptive; EU=European Union; HDL=high-density lipoprotein; LDL=low-density lipoprotein; LNG=levonorgestrel.
References
1. NEXTSTELLIS [package insert]. Greenville, NC: Mayne Pharma; April 2021. 2. Szarewski A, Mansour D, Shulman LP. 50 years of “The Pill”: celebrating a golden anniversary. J Fam Plann Reprod Health Care. 2010;36(4):231-238. 3. Hall KS, Trussell J. Types of combined oral contraceptives used by U.S. women. Contraception. 2012;86(6):659-665. 4. Coelingh Bennink HJT, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11(suppl 1):47-58. 5. New data on NEXTSTELLIS presented at ISSWSH conference. News release. Mayne Pharma. Accessed May 21, 2021. https://www.maynepharma.com/investor-relations/company-announcements 6. Foidart JM, Gaspard U, Pequeux C, et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: Brinton RD, Genazzani AR, Simoncini T, Stevenson JC, eds. Sex Steroids’ Effects on Brain, Heart and Vessels Volume 6: Frontiers in Gynecological Endocrinology. New York, NY: Springer International Publishing; 2019:169‐195. 7. Data on file. Clinical study report MIT‐Es0001‐C302. Mayne Pharma US. Greenville, NC. 8. Data on file. Clinical study report MIT‐Es0001‐C201. Mayne Pharma US. Greenville, NC. 9. Arnal JF, Lenfant F, Metivier R, et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol Rev. 2017;97(3):1045-1087. 10. Moggs JG, Orphanides G. Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep. 2001;2(9):775-781. 11. Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706-727. 12. Food and Drug Administration. FDA label database. Accessed May 21, 2021. https://nctr-crs.fda.gov/fdalabel/ui/search 13. Abot A, Fontaine C, Buscato M, et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328-1346. 14. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 2006;27(4):299-402. 15. Coelingh Bennink HJT, Heegaard AM, Visser M, Holinka CF, Christiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric. 2008;11(suppl 1):2-14. 16. Benoit T, Valera MC, Fontaine C, et al. Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear estrogen receptor α activation. Am J Pathol. 2017;187(11):2499-2507. 17. Shoham Z, Kopernik G. Tools for making correct decisions regarding hormone therapy. Part I: background and drugs. Fertil Steril. 2004;81(6):1447-1457. 18. Visser M, Foidart JM, Coelingh Bennink JT. In vitro effects of estetrol on receptor binding, drug targets, and human liver cell metabolism. Climacteric. 2008;11(suppl 1):64-68. 19. Blair R, Fang H, Branham WS, et al. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci. 2000;54:138-153. 20. Data on file. Clinical study report MIT‐Es0001‐C103. Mayne Pharma US. Greenville, NC. 21. Visser M, Holinka CF, Coelingh Bennink HJT. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008;11(suppl 1):31-40. 22. Apter, D, Zimmerman Y, Beekman L, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016;94(4):366-373. 23. Regidor PA, Schindler A. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8(47):83334-83342. 24. Blode H, Kowal K, Roth K, Reif S. Pharmacokinetics of drospirenone and ethinyl estradiol in Caucasian and Japanese women. Eur J Contracept Reprod Health Care. 2012;17(4):284-297. 25. Levy T, Yairi Y, Bar-Hava I, et al. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids. 2000;65(10-11):645-649. 26. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(suppl 1):3-63. 27. Ortho Tri-Cyclen [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; October 2013. 28. Aygestin [package insert]. Pomona, NY: Duramed Pharmaceuticals Inc; July 2007. 29. Data on file. Clinical study report MIT‐Es0001‐C301. Mayne Pharma US. Greenville, NC. 30. Data on file. Clinical study report MIT‐Es0001‐C202. Mayne Pharma US. Greenville, NC. 31. Food and Drug Administration. Prescription and over-the-counter drug product list: additions/deletions for prescription drug product list. August 2015. Accessed May 21, 2021. https://www.fda.gov/media/93516/download 32. Data on file. Clinical study report ES-C01/PR3095. Mayne Pharma US. Greenville, NC. 33. Data on file. Clinical study report ES-C02. Mayne Pharma US. Greenville, NC. 34. Mayne Pharma and Mithra announce FDA approval of new oral contraceptive NEXTSTELLIS®. News release. Mayne Pharma. Accessed May 21, 2021. https://www.maynepharma.com/media/2506/fda-approval-of-novel-oral-contraceptive-nextstellis.pdf 35. Electronic Code of Federal Regulations. IND safety reporting. 21 CFR §312.32. Accessed May 21, 2021. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32 36. Data on file. NEXTSTELLIS New Drug Application, Module 2.5: Clinical Overview. Mayne Pharma US. Greenville, NC. 37. Holinka CF, Gurpide E. In vivo effects of estetrol on the immature rat uterus. Biology of Reproduction. 1979;20:242-246. 38. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y. Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Climacteric. 2017;20(3):285-289. 39. Food and Drug Administration. Labeling for combined hormonal contraceptives: guidance for industry. Accessed May 11, 2021. https://www.fda.gov/media/110050/download

Rx request reviewed by healthcare professional (HCP)

Use your HSA, FSA or Credit Card for HCP review

Medication sent directly to your home or office

NEXTSTELLIS®

....

Find out if Sofdra™ (sofpironium bromide) gel, 12.45% is the right treatment for your excessive underarm sweating (primary axillary hyperhidrosis)....

Sofdra Medicaid

Get Sofdra™

Medicaid Adolescent

2nd One Month Supply Product

sofdra_man2_2808x1872

Sofdra_Man2_2808x1872

sofdrapep

Excessive underarm sweating (primary axillary hyperhidrosis) is a medical condition where underarm sweating occurs beyond what is needed to maintain normal body temperature. Talk to an independent, licensed telehealth provider today to see if Sofdra might be right for you.